Luis Calderón – General Manager, Alexion Mexico
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body’s immune response and can destroy healthy tissue in certain patients. Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor, approved in the United States, Canada, European Union, Australia, and Japan as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.
Contact details
Alexion
Paseo de los Tamarindos 90
Torre 1 Piso 6 Oficina A
Col. Bosque de la Lomas, Del. Cuajimalpa,
C.P. 05120, México DF
MEXICO
Tel: +52 (55) 5047 1500
Website: http://alxn.com/
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
According to a recent World Health Organization study, countries must allocate at least six percent of their GDP to research and development to be considered to have a healthy investment…
An ambassador for Philips’ global vision of spearheading innovation, business leader of Philips Personal Health Mexico, Eduardo Gutierrez, shares his insights on the key growth drivers in the segment, digitalization,…
Dr. Misael Uribe, chairman and founder at Médica Sur, showcases the reasons for the outstanding performance of the Médica Sur group, which offers high quality and ethical medical practices. Uribe…
Mexico’s medical device segment displays promising growth indicators, with innovative companies providing integrated and digital solutions now firmly embedded within the healthcare landscape. However, regulatory obstacles as well as a…
Hernán Fernández, Managing Partner at Angel Ventures, showcases the crucial role of private investments to enhance the national healthcare system as well as explains his action plan to raise the…
As a firm believer that the family should be at the epicenter of the social fabric of a society, Dr. Felipe Camargo, Medical Director and Founder of Ingenes, shares the…
Marco Cid, Director General of Investigacion Biomedica, shares how he successfully launched an innovative clinical research center (CRC) despite a challenging regulatory environment. He speaks about the inspiration behind his…
Spearheading the key governmental organization in charge of safeguarding the health of the Mexican capital, Minister of Health of Mexico City, José Armando Ahued Ortega, speaks about manoeuvring through the…
Spearheading one of the most trusted and recognizable pharmacy chain brands in the country, Isaac Valdivieso, Director General of Farmacia San Pablo, shares his insights about the company’s stance in…
The CEO of Accelerium Clinical Research, Ciro Garcia speaks about the trends currently impacting Mexico’s clinical research space, while detailing the company’s ambition to pivot from just one full-service research…
Ricardo Spínola, CEO at Farmapiel, explains his clear vision for the company and showcases the added value of Farmapiel’s product offering for both patients and healthcare professionals. Mr. Spínola you…
Positioning itself as a flexible local CRO with an in-depth knowledge of the Mexican market, iLS Clinical Research CEO, Alejandro Arias, shares his insights on how to be the ideal…
See our Cookie Privacy Policy Here
